Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07654842 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Fasenra: An Asthma Study

StatusEnrolling by Invitation
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrolling by invitation only
    • Eligibility criteria expanded, about 15 words
    • Study description expanded, about 9 words
    • Site contact updated
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Endeavor Health
37 trials monitored
See 3 trials at risk
Asthma
956 trials monitored
See 34 trials at risk
The goal of this observational study is to learn more about the effectiveness of benralizumab (Fasenra, 30 mg every 8 weeks) in maintaining asthma control in people with severe eosinophilic asthma. Participants will have electronic medication monitors fitted to their usual maintenance inhaler, as well as a study-provided anti-inflammatory rescue inhaler, albuterol-budesonide (AirSupra). These monitors will track when each inhaler is used. Participants will also upload time-stamped photos of their benralizumab administration to their electronic medical records.
Trial Details
NCT Number NCT07654842
Lead Sponsor Endeavor Health
Collaborators: AstraZeneca
Conditions
(from sponsor)		 Eosinophilic Asthma, Severe Asthma, Severe Eosinophilic Asthma, Asthma
Related terms Asthma, Pulmonary Eosinophilia
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov